MAPT and Alzheimer disease: Propranolol has shown neuroprotective effects in a preclinical AD model by reducing Aβ1-42 hippocampal accumulation and decreasing tau hyperphosphorylation through modulation of the GSK3β/JNK1 pathway [125].